Literature DB >> 15122807

Age related differences in humoral immune response to respiratory syncytial virus infection in adults.

Edward E Walsh1, Ann R Falsey.   

Abstract

The humoral immune response to Respiratory Syncytial Virus (RSV) was investigated in old and young adults. RSV was identified by culture and/or reverse transcription polymerase chain reaction (RT-PCR) in 52 elderly (mean age 74 years) and 15 young adults (mean age 33 years) with respiratory illness. Preinfection serum neutralizing and binding antibody levels were similar in the two age groups, although older persons had significantly greater serum neutralizing responses to group A RSV (log(2) 2.8 increase vs. 1.7, P = 0.001) and group B RSV (log(2) 2.8 vs. 1.3, P = 0.0008). Older persons also had significantly increased responses to the RSV F (log(2) 2.9 vs. 1.1, P < 0.0001), Ga (log(2) 2.1 vs. 1.3, P = 0.0007), and Gb proteins (log(2) 2.7 vs. 1.4, P = 0.0004). The exuberant antibody response seen in older adults may be a reflection of greater viral load and antigenic stimulation and/or a shift from Th1 to Th2 dominant immune response with aging. The relationship of immune response to disease pathogenesis in older persons deserves further study. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122807     DOI: 10.1002/jmv.20090

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  23 in total

1.  Effects of aging on the adaptive immune response to respiratory virus infections.

Authors:  Ross B Fulton; Steven M Varga
Journal:  Aging health       Date:  2009-12-01

2.  Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults.

Authors:  F Eun-Hyung Lee; Ann R Falsey; Jessica L Halliley; Iñaki Sanz; Edward E Walsh
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

3.  Spatial Memory Performance Associated with Measures of Immune Function in Elderly Female Rhesus Macaques.

Authors:  Gwendolen E Haley; Henryk F Urbanski; Steven G Kohama; Ilhem Messaoudi; Jacob Raber
Journal:  Eur Geriatr Med       Date:  2011-04-01       Impact factor: 1.710

4.  Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge.

Authors:  Jeanne H Schickli; David C Whitacre; Roderick S Tang; Jasmine Kaur; Heather Lawlor; Cory J Peters; Joyce E Jones; Darrell L Peterson; Michael P McCarthy; Gary Van Nest; David R Milich
Journal:  J Clin Invest       Date:  2015-03-09       Impact factor: 14.808

5.  Respiratory syncytial virus infection in older adults: an under-recognized problem.

Authors:  Angela R Branche; Ann R Falsey
Journal:  Drugs Aging       Date:  2015-04       Impact factor: 3.923

6.  T-Cell Responses in Adults During Natural Respiratory Syncytial Virus Infection.

Authors:  D Roumanes; A R Falsey; S Quataert; S Secor-Socha; F E-H Lee; H Yang; S Bandyopadhyay; J Holden-Wiltse; D J Topham; E E Walsh
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

7.  Viral shedding and immune responses to respiratory syncytial virus infection in older adults.

Authors:  Edward E Walsh; Derick R Peterson; Aja E Kalkanoglu; Frances Eun-Hyung Lee; Ann R Falsey
Journal:  J Infect Dis       Date:  2013-02-04       Impact factor: 5.226

Review 8.  The diagnosis of viral respiratory disease in older adults.

Authors:  H Keipp Talbot; Ann R Falsey
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

9.  Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Tatiana Chirkova; Sean O Todd; Thomas R Barnum; Kelsey A Gaston; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

10.  Humoral immunity to human metapneumovirus infection in adults.

Authors:  Ann R Falsey; Patricia A Hennessey; Maria A Formica; Mary M Criddle; Jamie M Biear; Edward E Walsh
Journal:  Vaccine       Date:  2009-12-08       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.